U.S. pharma big copyright scrapped two experimental weight loss drugs final calendar year—a at the time-every day pill, lotiglipron, as a consequence of elevated liver enzymes plus a two times-each day pill, danuglipron, as a consequence of robust side effects—but CEO Albert Bourla has stated the company is determined to “play and acquire”